Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.

Bernard Zinman; Bo Ahrén; Dietmar Neubacher; Sanjay Patel; Hans-Juergen Woerle; Odd Erik Johansen

doi:10.1016/j.jcjd.2015.06.010

Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.

Bernard Zinman, Bo Ahrén, Dietmar Neubacher, Sanjay Patel, Hans-Juergen Woerle, Odd Erik Johansen

Research output: Contribution to journal › Article › peer-review

Abstract

With the expanding armamentarium of noninsulin therapies for type 2 diabetes mellitus, the use of insulin with various oral agents is becoming more common. In this study, we assessed the efficacy and cardiovascular (CV) safety of the dipeptidyl peptidase-4 inhibitor linagliptin as add-on to insulin in patients with type 2 diabetes.

Original language	English
Pages (from-to)	50-57
Journal	Canadian Journal of Diabetes
Volume	40
Issue number	1
DOIs	https://doi.org/10.1016/j.jcjd.2015.06.010
Publication status	Published - 2016

Subject classification (UKÄ)

Endocrinology and Diabetes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jcjd.2015.06.010

http://www.ncbi.nlm.nih.gov/pubmed/26474870?dopt=Abstract

Cite this

@article{5edf55df249144a98d39f6638d3233a1,

title = "Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.",

abstract = "With the expanding armamentarium of noninsulin therapies for type 2 diabetes mellitus, the use of insulin with various oral agents is becoming more common. In this study, we assessed the efficacy and cardiovascular (CV) safety of the dipeptidyl peptidase-4 inhibitor linagliptin as add-on to insulin in patients with type 2 diabetes.",

author = "Bernard Zinman and Bo Ahr{\'e}n and Dietmar Neubacher and Sanjay Patel and Hans-Juergen Woerle and Johansen, {Odd Erik}",

year = "2016",

doi = "10.1016/j.jcjd.2015.06.010",

language = "English",

volume = "40",

pages = "50--57",

journal = "Canadian Journal of Diabetes",

issn = "2352-3840",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.

AU - Zinman, Bernard

AU - Ahrén, Bo

AU - Neubacher, Dietmar

AU - Patel, Sanjay

AU - Woerle, Hans-Juergen

AU - Johansen, Odd Erik

PY - 2016

Y1 - 2016

N2 - With the expanding armamentarium of noninsulin therapies for type 2 diabetes mellitus, the use of insulin with various oral agents is becoming more common. In this study, we assessed the efficacy and cardiovascular (CV) safety of the dipeptidyl peptidase-4 inhibitor linagliptin as add-on to insulin in patients with type 2 diabetes.

AB - With the expanding armamentarium of noninsulin therapies for type 2 diabetes mellitus, the use of insulin with various oral agents is becoming more common. In this study, we assessed the efficacy and cardiovascular (CV) safety of the dipeptidyl peptidase-4 inhibitor linagliptin as add-on to insulin in patients with type 2 diabetes.

U2 - 10.1016/j.jcjd.2015.06.010

DO - 10.1016/j.jcjd.2015.06.010

M3 - Article

C2 - 26474870

SN - 2352-3840

VL - 40

SP - 50

EP - 57

JO - Canadian Journal of Diabetes

JF - Canadian Journal of Diabetes

IS - 1

ER -

Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Cite this